Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...

A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was ...

There has been no halt in trading and shares are expected to continue trading unabated. This press release is for informational purposes only. It shall not constitute an offer to sell or exchange nor ...

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Argenx Se (ARGX – Research Report) yesterday and set a price target ...

A special blood drive was held Monday afternoon to honor a Cranston High School East teacher battling leukemia.

A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall ...

It's hard to believe that I've now reached the 6-month point of my treatment for Chronic Myeloid Leukemia (CML) at Roswell ...

PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by ...

A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.